Ordered nanoporous silica as carriers for improved delivery of water insoluble drugs: A comparative study between three dimensional and two dimensional macroporous silica

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 4015-4031

  Wang, Ying ^a   Zhao, Qinfu ^a   Hu, Yanchen ^a   Sun, Lizhang ^a   Bai, Ling ^a   Jiang, Tongying ^a   Wang, Siling ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

3D ordered macroporous silica; In vitro cytotoxicity; In vitro dissolution; Mesoporous silica; Poorly soluble drugs; Stability test

Indexed keywords

INDOMETACIN; MCM 41; SBA 15; SILICON DIOXIDE; UNCLASSIFIED DRUG;

ADSORPTION; ARTICLE; BIOCOMPATIBILITY; COMPARATIVE STUDY; CONTROLLED STUDY; CRYSTALLIZATION; CYTOTOXICITY; DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; GEOMETRY; HUMAN; HUMAN CELL; HYDROPHILICITY; PARTICLE SIZE; SCANNING ELECTRON MICROSCOPY; X RAY DIFFRACTION;

3D ORDERED MACROPOROUS SILICA; IN VITRO CYTOTOXICITY; IN VITRO DISSOLUTION; MESOPOROUS SILICA; POORLY SOLUBLE DRUGS; STABILITY TEST;

CACO-2 CELLS; CELL SURVIVAL; DIFFUSION; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; INDOMETHACIN; NANOCAPSULES; NANOPORES; PARTICLE SIZE; POROSITY; SILICON DIOXIDE; SOLUBILITY; WATER;

EID: 84886037623     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S52605     Document Type: Article

References (56)

1. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1-3): 3-26.
2. Fahr A, Liu X. Drug delivery strategies for poorly water-soluble drugs. Expert Opin Drug Deliv. 2007;4(4):403-416.
3. Dressman J, Christos R. Drug solubility: how to measure it, how to improve it. Adv Drug Del Rev. 2007;59(7):531-532.
4. Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci. 2003;18(2):113-120.
5. Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001;47(1):3-19.
6. Hauss DJ. Oral lipid-based formulations. Adv Drug Deliv Rev. 2007;59(7):667-676.
7. Cole ET, Cadé D, Benameur H. Challenges and opportunities in the encapsulation of liquid and semi-solid formulations into capsules for oral administration. Adv Drug Deliv Rev. 2008;60(6):747-756.
8. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm. 2000;50(1):47-60.
9. Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today. 2007;12(23-24):1068-1075.
10. Sharma S, Sher P, Badve S, Pawar AP. Adsorption of meloxicam on porous calcium silicate: characterization and tablet formulation. AAPS PharmSciTech. 2005;6(4):E618-E625.
11. Friedrich H, Fussnegger B, Kolter K, Bodmeier R. Dissolution rate improvement of poorly water-soluble drugs obtained by adsorbing solutions of drugs in hydrophilic solvents onto high surface area carriers. Eur J Pharm Biopharm. 2006;62(2):171-177.
12. Sanganwar GP, Gupta RB. Dissolution-rate enhancement of fenofibrate by adsorption onto silica using supercritical carbon dioxide. Int J Pharm. 2008;360(1-2):213-218.
13. Kinoshita M, Baba K, Nagayasu A, et al. Improvement of solubility and oral bioavailability of a poorly water-soluble drug, TAS-301, by its melt-adsorption on a porous calcium silicate. J Pharm Sci. 2002;91(2): 362-370.
14. Smirnova I, Mamic J, Arlt W. Adsorption of drugs on silica aerogels. Langmuir. 2003;19(20):8521-8525.
15. Tan A, Simovic S, Davey AK, Rades T, Prestidge CA. Silica-lipid hybrid (SLH) microcapsules: a novel oral delivery system for poorly soluble drugs. J Control Release. 2009;134(1):62-70.
16. Bahl D, Bogner RH. Amorphization of Indomethacin by Co-Grinding with Neusilin US2: amorphization kinetics, physical stability and mechanism. Pharm Res. 2006;23(10):2317-2325.
17. Smirnova I, Suttiruengwong S, Seiler M, Arlt W. Dissolution rate enhancement by adsorption of poorly soluble drugs on hydrophilic silica aerogels. Pharm Dev Technol. 2004;9(4):443-452.
18. Quintanar-Guerrero D, Ganem-Quintanar A, Nava-Arzaluz MG, Piñón-Segundo E. Silica xerogels as pharmaceutical drug carriers. Expert Opin Drug Deliv. 2009;6(5):485-498.
19. Slowing II, Vivero-Escoto JL, Wu CW, Lin VS. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev. 2008;60(11):1278-1288.
20. Colilla M, Manzano M, Vallet-Regí M. Recent advances in ceramic implants as drug delivery systems for biomedical applications. Int J Nanomedicine. 2008;3(4):403-414.
21. Kresge C, Leonowicz M, Roth W, Vartuli J, Beck J. Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism. Nature. 1992;359(6397):710-712.
22. Chen B, Wang Z, Quan G, et al. In vitro and in vivo evaluation of ordered mesoporous silica as a novel adsorbent in liquisolid formulation. Int J Nanomedicine. 2012;7:199-209.
23. Vallet-Regí M, Balas F, Colilla M, Manzano M. Drug confinement and delivery in ceramic implants. Drug Metab Lett. 2007;1(1):37-40.
24. Heikkilä T, Salonen J, Tuura J, et al. Mesoporous silica material TUD-1 as a drug delivery system. Int J Pharm. 2007;331(1):133-138.
25. Vallet-Regí M, Doadrio JC, Doadrio AL, Izquierdo-Barba I, Pérez-Pariente J. Hexagonal ordered mesoporous material as a matrix for the controlled release of amoxicillin. Solid State Ionics. 2004;172(1-4):435-439.
26. Holland BT, Blanford CF, Stein A. Synthesis of macroporous minerals with highly ordered three-dimensional arrays of spheroidal voids. Science. 1998;281(5376):538-540.
27. Lytle JC, Yan H, Ergang NS, Smyrl WH, Stein A. Structural and electrochemical properties of three-dimensionally ordered macroporous tin(IV) oxide films. J Mater Chem. 2004;14:1616-1622.
28. Lee K, Lytle J, Ergang N, Oh S, Stein A. Synthesis and rate performance of monolithic macroporous carbon electrodes for lithium-ion secondary batteries. Adv Funct Mater. 2005;15(4):547-556.
29. Velev OD, Lenhoff AM. Colloidal crystals as templates for porous materials. Curr Opin Colloid In. 2000;5(1-2):56-63.
30. Stein A, Schroden RC. Colloidal crystal templating of three-dimensionally ordered macroporous solids: materials for photonics and beyond. Curr Opin Solid St Mater Sci. 2001;5(6):553-564.
31. Hancock BC. Disordered drug delivery: destiny, dynamics and the Deborah number. J Pharm Pharmacol. 2002;54(6):737-746.
32. Yoshioka M, Hancock BC, Zografi G. Crystallization of indomethacin from the amorphous state below and above its glass transition temperature. J Pharm Sci. 1994;83(12):1700-1705.
33. Williams AC, Timmins P, Lu M, Forbes RT. Disorder and dissolution enhancement: deposition of ibuprofen on to insoluble polymers. Eur J Pharm Sci. 2005;26(3-4):288-294.
34. Tang F, Li L, Chen D. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Adv Mater Weinheim. 2012;24(12): 1504-1534.
35. Fu C, Liu T, Li L, Liu H, Chen D, Tang F. The absorption, distribution, excretion and toxicity of mesoporous silica nanoparticles in mice following different exposure routes. Biomaterials. 2013;34(10):2565-2575.
36. Guzmán E, Liggieri L, Santini E, et al. Influence of silica nanoparticles on dilational rheology of DPPC-palmitic acid Langmuir monolayers. Soft Matter. 2012;8:3938-3948.
37. Heikkilä T, Santos HA, Kumar N, et al. Cytotoxicity study of ordered mesoporous silica MCM-41 and SBA-15 microparticles on Caco-2 cells. Eur J Pharm Biopharm. 2010;74(3):483-494.
38. Di Pasqua AJ, Sharma KK, Shi YL, et al. Cytotoxicity of mesoporous silica nanomaterials. J Inorg Biochem. 2008;102(7):1416-1423.
39. Lee S, Yun HS, Kim SH. The comparative effects of mesoporous silica nanoparticles and colloidal silica on inflammation and apoptosis. Biomaterials. 2011;32(35):9434-9443.
40. Wang F, Hui H, Barnes TJ, Barnett C, Prestidge CA. Oxidized mesoporous silicon microparticles for improved oral delivery of poorly soluble drugs. Mol Pharm. 2010;7(1):227-236.
41. Hu Y, Wang J, Zhi Z, Jiang T, Wang S. Facile synthesis of 3D cubic mesoporous silica microspheres with a controllable pore size and their application for improved delivery of a water-insoluble drug. J Colloid Interface Sci. 2011;363(1):410-417.
42. Cai Q, Lin WY, Xiao FS, Pang WQ, Chen XH, Zou BS. The preparation of highly ordered MCM-41 with extremely low surfactant concentration. Micropor Mesopor Mater. 1999;32(1-2):1-15.
43. Zhao D, Feng J, Huo Q, et al. Triblock copolymer syntheses of mesoporous silica with periodic 50 to 300 angstrom pores. Science. 1998;279(5350):548-552.
44. Zhang J, Jin Y, Li C, et al. Creation of three-dimensionally ordered macroporous Au/CeO2 catalysts with controlled pore sizes and their enhanced catalytic performance for formaldehyde oxidation. Appl Catal B: Environmental. 2009;91(1-2):11-20.
45. Hu Y, Zhi Z, Wang T, Jiang T, Wang S. Incorporation of indomethacin nanoparticles into 3-D ordered macroporous silica for enhanced dissolution and reduced gastric irritancy. Eur J Pharm Biopharm. 2011;79(3): 544-551.
46. Barzegar-Jalali M, Maleki N, Garjani A, et al. Enhancement of dissolution rate and anti-inflammatory effects of piroxicam using solvent deposition technique. Drug Dev Ind Pharm. 2002;28(6):681-686.
47. Hu Y, Zhi Z, Zhao Q, et al. 3D cubic mesoporous silica microsphere as a carrier for poorly soluble drug carvedilol. Micropor Mesopor Mater. 2012;147(1):94-101.
48. Sing K, Everett D, Haul R, et al. Reporting physisorption data for gas/solid systems - with special reference to the determination of surface area and porosity. Pure Appl Chem. 1985;57(4):603-619.
49. Mellaerts R, Mols R, Jammaer JA, et al. Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica. Eur J Pharm Biopharm. 2008;69(1): 223-230.
50. Ji C, Barrett A, Poole-Warren LA, Foster NR, Dehghani F. The development of a dense gas solvent exchange process for the impregnation of pharmaceuticals into porous chitosan. Int J Pharm. 2010;391(1-2): 187-196.
51. Madieh S, Simone M, Wilson W, Mehra D, Augsburger L. Investigation of drug-porous adsorbent interactions in drug mixtures with selected porous adsorbents. J Pharm Sci. 2007;96(4):851-863.
52. Blagden N, de Matas M, Gavan PT, York P. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Deliv Rev. 2007;59(7):617-630.
53. Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res. 2000;17(4):397-404.
54. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1-2):55-63.
55. Li Y, Sun L, Jin M, et al. Size-dependent cytotoxicity of amorphous silica nanoparticles in human hepatoma HepG2 cells. Toxicol In Vitro. 2011;25(7):1343-1352.
56. Di Pasqua AJ, Sharma KK, Shi YL, et al. Cytotoxicity of mesoporous silica nanomaterials. J Inorg Biochem. 2008;102(7):1416-1423.